Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

Group 1 - The first domestic nine-valent HPV vaccine was administered in Fuyang, Anhui Province, on November 26, 2025, benefiting women aged 9 to 45 and promoting primary prevention of cervical cancer [2] - A recent conference in Beijing gathered experts from various cancer fields to discuss advancements in diagnosis and treatment, emphasizing the importance of clinical research innovation in improving patient outcomes [3][4] Group 2 - Significant progress has been made in the treatment of gastrointestinal tumors in China, with innovative drugs driving updates in authoritative treatment guidelines and new clinical research strategies emerging [4] - The treatment of urological tumors is evolving towards a combination of surgery and medication, with advancements in minimally invasive techniques and drug therapies improving patient outcomes [5] Group 3 - The treatment landscape for nasopharyngeal carcinoma is being optimized, with immunotherapy becoming a first-line option for advanced cases, significantly improving survival rates [6] - CAR-T cell therapy and targeted drugs are providing long-term survival opportunities for patients with hematological tumors, although challenges remain in early diagnosis and treatment accessibility [6] Group 4 - The industry is moving towards a new era of precision, individualized, and multidisciplinary collaboration in cancer treatment, with a consensus on the need to enhance diagnostic and treatment systems [7] - The "People's Good Doctor · Camellia Plan" aims to promote the translation of research findings into clinical practice and improve healthcare services for the public [8]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發。 董事會欣然宣佈，本公司子公司廣州泰和腫瘤醫院質子治療中心（以下簡稱「廣州 醫院質子中心」）自2024年12月16日起至今，已正式運營一周年。公司高度重視 質子治療中心的臨床能力建設，堅持加強與國際先進醫療機構合作科研，與國際 質子治療技術同步發展，通過引進高端醫療人才、加強技術研發與學術交流等方 式，持續提升診療水平。截至目前，廣州醫院質子中心的臨床服務能力已得到充 分驗證，各項運營指標表現良好。 廣州醫院質子中心四間質子治療室已經全部啟用，累計為550位患者提供質子治 療服務，單月新增患者超過80人，服務能力持續提升。服務患者範圍覆蓋國內31 個省級行政區以及20多個國家和地區，接受質子治療的患者年齡從1歲至91歲。 2025年7月，廣州醫 ...

智通财经APP讯，复旦张江(688505.SH)发布公告，公司于近日收到国家药品监督管理局核准签发的 《受理通知书》，注射用FZ-P001钠用于已知或疑似肺癌患者术中恶性病变可视化的II期临床试验申请 获得受理。 注射用FZ-P001钠为公司自主研发的化学药品1类新化合物，是一种创新型光敏剂，其活性成分为叶酸 受体靶向小分子与花菁类光敏剂偶联而成的分子，可靶向叶酸受体α(FRα)高表达的恶性肿瘤组织并在近 红外区间荧光显影。公司计划使用该药物开发术中荧光指引技术，指示肿瘤恶性病变组织残留与切缘状 态，旨在提高相关实体瘤(如卵巢癌、肺癌等)手术切除效果，为肿瘤外科的精准导航手术提供兼具分子 靶向特异性和多维生物感知的创新解决方案。 ...

12月19日，随着三个质子治疗舱同时运行，华中科技大学同济医学院附属协和医院（以下简称协和医 院）质子医学中心正式启用。 作为当前国内技术最先进、规模最大的质子中心之一，协和质子中心率先实现"三舱同启"，并配备全国 首台ProBeam 360°质子放疗系统。这标志着华中地区肿瘤精准治疗水平迎来质的飞跃。 协和医院院长夏家红介绍，医院专项投入200万元资金，用于支持儿童肿瘤治疗公益项目。该资金将覆 盖100名儿童肿瘤患者，为每位患者减免2万元治疗费，切实减轻患者家庭负担。此举既是响应国家卫生 健康委对公立医院公益性的要求，也是医院助力儿童肿瘤治疗、承担社会责任的具体体现。 协和医院党委书记张玉表示，质子医学中心的启用，是协和医院积极响应国家"十五五"发展规划、实施 健康优先发展战略的最新举措。医院将继续坚持"科技创新"与"人文关怀"双轮驱动，利用百年协和的多 学科综合优势，将设备的技术优势转化为科研与临床特长，为更多肿瘤患者提供国内领先、国际一流的 质子治疗"中国方案"。 （文章来源：科技日报） 为彰显公立医院公益性，当天，协和医院对外宣布，该院同步推出"肿瘤患儿关爱行动"，为经评估适合 质子治疗的前100位儿 ...

19日，在协和质子医学中心首批接受治疗的3名患者均为4岁至10岁儿童。10岁的武汉男 孩洋洋（化名）罹患一种罕见的脑瘤——毛细胞黏液型星形细胞瘤，由于肿瘤位于中枢神经 系统深处，毗邻重要脑功能区，常规放疗风险极大。协和质子医学中心团队经过综合评估， 为洋洋制定了"质子刀"计划。洋洋躺在治疗床上，经历10来分钟的精准摆位，真正的放疗时 间仅用了10余秒。他说："没有任何感觉，看得见机器快速旋转，好神奇！"未来他还将经历 每周5次、共计30次的治疗。 协和医院肿瘤中心主任杨坤禹教授介绍，"质子刀"具备独特的"布拉格峰"效应，射线在 到达肿瘤前能量释放极低，抵达病灶则瞬间释放最大能量，随后能量迅速跌落为零，实 现"专灭癌细胞、不伤好细胞"的精准爆破，将副反应降到近乎为零。协和"质子刀"系统搭载 了高精度笔形束扫描技术，能360度无死角瞄准靶区，精度校准至亚毫米级远高于国际标 准，即便肿瘤随呼吸移动，系统也能即时"追踪"和"锁定"。"质子治疗是目前国际推荐的儿 童脑肿瘤及实体瘤的优选方案，也适用于需要放疗的实体瘤成年患者。"杨坤禹说。 编辑：赖俊 质子射线治疗被比作"质子刀"，是当下最前沿的肿瘤放疗技术。12月19日 ...

智通财经APP讯，中国同辐(01763)发布公告，近日，国家药品监督管理局药品审评中心(CDE)官网信息 显示公司附属公司深圳市中核海得威生物科技有限公司(中核海得威)自主研发的2.2类改良新药"注射用 硼[B]法仑"(BNCT硼药：硼中子俘获疗法，Boron neutron capture therapy)临床试验申请获批(通知书编 号：2025LP03425)。 此外，中核海得威"注射用硼[B]法仑"临床试验申请获批标志着中核海得威BNCT药械协同研发领域取得 突破性成果，正式迈入临床转化新阶段，为"健康中国"战略下的精准肿瘤治疗注入核科技新动能，为全 球肿瘤治疗贡献"中国方案"。 中核海得威自研的国产"注射用硼[B]法仑"针对对放化疗不敏感、复发性、难治性、浸润性、中晚期、 局部转移的头颈部肿瘤具有显著临床优势，且治疗疗程短(仅需1-2次)、毒副作用低，代表了现代肿瘤精 准医学的发展方向和前沿创新，为患者提供了全新的治疗选择，推动了肿瘤治疗领域的创新与突破。 ...

Core Viewpoint - China Nuclear Industry's subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has received approval for clinical trial application of its self-developed 2.2 class improved new drug, "Injectable Boron [10B] Falun" (BNCT boron drug), marking a significant advancement in the field of tumor treatment [1] Group 1 - The drug targets head and neck tumors that are resistant to radiotherapy and chemotherapy, showing significant clinical advantages, including a short treatment course of only 1-2 sessions and low toxicity [1] - This approval signifies a breakthrough in the collaborative research and development of BNCT drug-device integration, entering a new phase of clinical transformation [1] - The development aligns with the "Healthy China" strategy, injecting new momentum from nuclear technology into precise tumor treatment and contributing a "Chinese solution" to global cancer treatment [1]

Group 1: Financing Trends - The technology and manufacturing sectors are the primary focus of capital investment, with significant financing activity observed in semiconductors, robotics, and biomedicine [1][3] - A total of 41 financing events occurred in the domestic primary market from December 8 to December 14, with 34 disclosing amounts totaling approximately 10.36 billion RMB [1][2] Group 2: Sector Highlights - The biomedicine sector completed 7 financing rounds totaling approximately 630 million RMB, while the artificial intelligence sector saw 6 rounds with disclosed amounts around 1.2 billion RMB [3][4] - Notable financing events include Suzhou Saintin Biotech's over 110 million USD B round, and Desheng Medical's 108 million USD B round, indicating strong interest in RNAi therapies and precision oncology [1][11][12] Group 3: Regional Distribution - Financing activities were concentrated in Jiangsu, Shanghai, and Beijing, with 11, 9, and 6 financing events respectively [5][6] Group 4: Active Investment Institutions - Nanshan Zhanxin Investment and Longpan Investment were particularly active, completing 4 and 3 financing rounds respectively, primarily in technology and healthcare sectors [7][8] Group 5: Notable Company Financing - Airwallex, a global cross-border payment platform, completed a 330 million USD G round, achieving a valuation of 8 billion USD [9] - Beijing Tongjia Hongrui Technology raised over 1 billion RMB in a B+ round, focusing on semiconductor materials [20] - Shenzhen New Voice Semiconductor secured nearly 300 million RMB in a C round, emphasizing its leadership in automotive-grade filters [17] - Hangzhou Yundongchu Technology raised over 500 million RMB in a C round, focusing on four-legged and humanoid robots [19]

Core Viewpoint - The approval of the IND for IDEAYA's dual-target ADC project IDE034 by the FDA marks a significant advancement in the development of innovative cancer therapies, potentially enhancing the company's market position and investor interest [1][2]. Group 1: Company Developments - 百奥赛图-B's stock rose over 3%, reaching 31.86 HKD with a trading volume of 12.99 million HKD following the announcement of FDA IND approval for IDEAYA's IDE034 project [1]. - IDEAYA Biosciences, Inc. plans to initiate patient enrollment for the Phase I clinical trial in Q1 2026, focusing on solid tumors co-expressing B7H3 and PTK7, including lung cancer, colorectal cancer, head and neck cancer, and ovarian/gynecological tumors [1]. Group 2: Clinical Research Insights - Preclinical studies indicate that IDE034 demonstrates deep and durable tumor regression in various B7H3/PTK7 positive tumor models, showcasing strong anti-tumor activity [2]. - IDEAYA intends to explore a combination therapy strategy with its PARG inhibitor IDE161 to enhance the durability of treatment effects, with plans to present additional data on the combined treatment mechanism at a major medical conference in H1 2026 [2]. - The co-expression rates of B7H3/PTK7 in solid tumors are approximately 30% in lung cancer, 46% in colorectal cancer, and 27% in head and neck cancer, indicating broad clinical applicability [2].